Milwaukee — The main component of Botox (onabotulinumtoxinA, Allergan) may provide a modest ancillary benefit to patients who suffer from chronic migraines and chronic daily headaches when compared to placebo, according to a report in the Journal of the American Medical Association.
"Botulinum toxin A compared with placebo was associated with a small-to-modest benefit for chronic daily headaches and chronic migraines, but was not associated with fewer episodic migraine or chronic tension-type headaches per month," the authors wrote.
HealthDay News reports that researchers with the Medical College of Wisconsin, Milwaukee, conducting pooled analyses noted a reduction in headaches per month in study participants affected by either chronic daily headaches or chronic migraines. No statistically significant correlation was seen between botulinum toxin A and reduction in episodic migraine headaches or chronic tension-type headaches.
Compared to placebo, botulinum toxin A was associated with more occurrences of adverse effects, such as skin tightness, neck stiffness, neck pain, muscle weakness, paresthesias and blepharoptosis.
Go back to the Cosmetic Surgery Times eNews newsletter.